Sale!

CYP2C19 Gene CYP2C19 related poor drug metabolism Genetic Test Cost

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The CYP2C19 gene plays a critical role in the body’s ability to metabolize various medications. Variations in this gene can significantly impact how individuals respond to certain drugs, making the CYP2C19-related poor drug metabolism genetic test an essential tool for personalized medicine. This test identifies specific genetic variants of the CYP2C19 gene that can lead to reduced or enhanced enzyme activity, affecting the metabolism of drugs such as antidepressants, proton pump inhibitors, antiepileptics, and certain blood thinners. Understanding an individual’s CYP2C19 genotype can help healthcare providers make more informed decisions about drug choice and dosage, potentially reducing the risk of adverse drug reactions and improving therapeutic outcomes.

Conducted at DNA Labs UAE, a leading facility in genetic testing, the test costs 4400 AED. The process involves a simple and non-invasive sample collection, after which the sample is analyzed to determine the individual’s CYP2C19 genotype. The results of this test can provide valuable information for tailoring medication regimens to fit the genetic makeup of the patient, ultimately contributing to more effective and safer healthcare practices.

Description

CYP2C19 Gene CYP2C19 related poor drug metabolism Genetic Test

Test Name: CYP2C19 Gene CYP2C19 related poor drug metabolism Genetic Test

Components: DNA sequencing of CYP2C19 gene

Price: 4400.0 AED

Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card

Report Delivery: 3 to 4 Weeks

Method: NGS Technology

Test type: Metabolic Disorders

Doctor: General Physician

Test Department: Genetics

Pre Test Information: Clinical History of Patient who is going for CYP2C19 Gene CYP2C19 related poor drug metabolism NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with CYP2C19 related poor drug metabolism.

Test Details:

The CYP2C19 gene is responsible for producing an enzyme called cytochrome P450 2C19, which plays a crucial role in metabolizing various drugs in the body. However, some individuals may have genetic variations in the CYP2C19 gene that can lead to poor drug metabolism.

To determine if an individual has CYP2C19-related poor drug metabolism, a Next-Generation Sequencing (NGS) genetic test can be conducted. NGS is a high-throughput DNA sequencing technology that allows for the analysis of multiple genes simultaneously.

During the test, a sample of the individual’s DNA is collected, typically through a blood or saliva sample. The DNA is then sequenced using NGS technology to identify any genetic variations in the CYP2C19 gene.

The results of the NGS genetic test can provide information about the specific genetic variations present in the CYP2C19 gene and their potential impact on drug metabolism. This information can be used by healthcare professionals to personalize medication dosages and avoid drugs that may be poorly metabolized in individuals with CYP2C19-related poor drug metabolism.

It is important to note that NGS genetic testing should be performed and interpreted by qualified healthcare professionals who specialize in genetics, as the results may have implications for medication management and treatment decisions.

Test Name	CYP2C19 Gene CYP2C19 related poor drug metabolism Genetic Test
Components
Price	4400.0 AED
Sample Condition	Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery	3 to 4 Weeks
Method	NGS Technology
Test type	Metabolic Disorders
Doctor	General Physician
Test Department:	Genetics
Pre Test Information	Clinical History of Patient who is going for CYP2C19 Gene CYP2C19 related poor drug metabolism NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with CYP2C19 related poor drug metabolism
Test Details	The CYP2C19 gene is responsible for producing an enzyme called cytochrome P450 2C19, which plays a crucial role in metabolizing various drugs in the body. However, some individuals may have genetic variations in the CYP2C19 gene that can lead to poor drug metabolism. To determine if an individual has CYP2C19-related poor drug metabolism, a Next-Generation Sequencing (NGS) genetic test can be conducted. NGS is a high-throughput DNA sequencing technology that allows for the analysis of multiple genes simultaneously. During the test, a sample of the individual’s DNA is collected, typically through a blood or saliva sample. The DNA is then sequenced using NGS technology to identify any genetic variations in the CYP2C19 gene. The results of the NGS genetic test can provide information about the specific genetic variations present in the CYP2C19 gene and their potential impact on drug metabolism. This information can be used by healthcare professionals to personalize medication dosages and avoid drugs that may be poorly metabolized in individuals with CYP2C19-related poor drug metabolism. It is important to note that NGS genetic testing should be performed and interpreted by qualified healthcare professionals who specialize in genetics, as the results may have implications for medication management and treatment decisions.